Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. (Q53396593)

From Wikidata

Jump to navigation Jump to search

scientific article published on 4 August 2015

Language	Label	Description	Also known as
English	Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.	scientific article published on 4 August 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

based on heuristic

inferred from title

evasion of host immune response

1 reference

based on heuristic

inferred from title

Klaus H Metzeler

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

Irmela Jeremias

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

author name string

C Krupka

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

P Kufer

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

R Kischel

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

G Zugmaier

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

F S Lichtenegger

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

T Köhnke

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

T Altmann

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

S Schneider

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

M Fiegl

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

K Spiekermann

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

P A Bauerle

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

W Hiddemann

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

G Riethmüller

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

M Subklewe

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

publication date

4 August 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

484-491

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

PD-1 and its ligands in tolerance and immunity

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Molecular mechanisms of T cell co-stimulation and co-inhibition

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Cancer immunotherapy comes of age

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Tumor Immunotherapy Directed at PD-1

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Nivolumab in NSCLC: latest evidence and clinical potential

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

The targeting of immunosuppressive mechanisms in hematological malignancies

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Bispecific T-cell engaging antibodies for cancer therapy

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

The past and future of CD33 as therapeutic target in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Coexpression of Tim-3 and PD-1 identifies a CD8 T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

https://api.crossref.org/works/10.1038/LEU.2015.214

21 January 2018

Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

1 reference

https://pubmed.ncbi.nlm.nih.gov/26239198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26239198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flow cytometric analysis of different CD14 epitopes can help identify immature monocytic populations

1 reference

https://pubmed.ncbi.nlm.nih.gov/26239198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26239198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/26239198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26239198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26239198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2015.214

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26239198 AND SRC:MED&resulttype=core&format=json

20 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53396593&oldid=2212106003"